PURE Bioscience, Inc.
PURE
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.95M
Close$
Share Statistics
| Market cap | $8.95 Million |
|---|---|
| Enterprise Value | $14.90 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.02 |
| Beta | 0.11 |
| Outstanding Shares | 111,886,473 |
Return
| Return on Equity | 34.45% |
|---|---|
| Return on Assets | -274.24% |
| Return on Invested Capital | 79.27% |
Valuation & Multiples
| P/E Ratio | -4.14 |
|---|---|
| PEG | 254.26 |
| Price to Sales | - |
| Price to Book Ratio | -0.07 |
| Enterprise Value to Revenue | 6.19 |
| Enterprise Value to EBIT | -8.29 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.41 |
| Debt to Equity | -0.98 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
June 16, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PURE Bioscience, Inc.
11 employees
CEO: Mr. Robert F. Bartlett PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufacture...